Our top pick for
ICU Medical, Inc is a medical instruments & supplies business based in the US. ICU Medical shares (ICUI) are listed on the NASDAQ and all prices are listed in US Dollars. ICU Medical employs 8,000 staff and has a trailing 12-month revenue of around USD$1.3 billion.
Since the stock market crash in March caused by coronavirus, ICU Medical's share price has had significant negative movement.
Its last market close was USD$188.82, which is 12.47% down on its pre-crash value of USD$215.73 and 19.50% up on the lowest point reached during the March crash when the shares fell as low as USD$158.01.
If you had bought USD$1,000 worth of ICU Medical shares at the start of February 2020, those shares would have been worth USD$860.31 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$998.86.
|Latest market close||USD$188.82|
|52-week range||USD$155.36 - USD$236.505|
|50-day moving average||USD$191.0235|
|200-day moving average||USD$193.1397|
|Wall St. target price||USD$222.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.85|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||0.30%|
|1 month (2020-10-23)||-2.06%|
|3 months (2020-08-24)||3.41%|
|6 months (2020-05-22)||-1.16%|
|1 year (2019-11-22)||0.98%|
|2 years (2018-11-23)||-19.02%|
|3 years (2017-11-24)||-13.35%|
|5 years (2015-11-24)||70.83%|
Valuing ICU Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICU Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ICU Medical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 53x. In other words, ICU Medical shares trade at around 53x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ICU Medical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.8765. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICU Medical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ICU Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$236.7 million.
The EBITDA is a measure of a ICU Medical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.3 billion|
|Operating margin TTM||12.35%|
|Gross profit TTM||USD$488.2 million|
|Return on assets TTM||5.56%|
|Return on equity TTM||6.08%|
|Market capitalisation||USD$4 billion|
TTM: trailing 12 months
There are currently 262,444 ICU Medical shares held short by investors – that's known as ICU Medical's "short interest". This figure is 12.2% down from 298,919 last month.
There are a few different ways that this level of interest in shorting ICU Medical shares can be evaluated.
ICU Medical's "short interest ratio" (SIR) is the quantity of ICU Medical shares currently shorted divided by the average quantity of ICU Medical shares traded daily (recently around 152583.72093023). ICU Medical's SIR currently stands at 1.72. In other words for every 100,000 ICU Medical shares traded daily on the market, roughly 1720 shares are currently held short.
However ICU Medical's short interest can also be evaluated against the total number of ICU Medical shares, or, against the total number of tradable ICU Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ICU Medical's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ICU Medical shares in existence, roughly 10 shares are currently held short) or 0.0187% of the tradable shares (for every 100,000 tradable ICU Medical shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ICU Medical.
Find out more about how you can short ICU Medical stock.
We're not expecting ICU Medical to pay a dividend over the next 12 months.
ICU Medical's shares were split on a 3:2 basis on 18 March 2002. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your ICU Medical shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for ICU Medical shares which in turn could have impacted ICU Medical's share price.
Over the last 12 months, ICU Medical's shares have ranged in value from as little as $155.36 up to $236.505. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ICU Medical's is 0.6691. This would suggest that ICU Medical's shares are less volatile than average (for this exchange).
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in vascular therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency connectors; SwabCap disinfecting caps; Tego hemodialysis connectors; NovaCath and SuperCath peripheral intravenous (IV) catheters; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride irrigation, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. Further, it provides ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms, as well as related professional services. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.